<DOC>
	<DOCNO>NCT01393743</DOCNO>
	<brief_summary>This study design evaluate efficacy , safety , pharmacokinetics ( PK ) perampanel Primary Generalized Tonic Clonic ( PGTC ) seizure frequency adolescent adult maintain one two stable antiepileptic drug .</brief_summary>
	<brief_title>A Efficacy Safety Study Adjunctive Perampanel Primary Generalized Tonic Clonic Seizures</brief_title>
	<detailed_description>This study multicenter , randomize , double-blind , placebo-controlled , parallel-group , adjunctive-therapy study open-label Extension Phase . The Core Study consist 2 phase : Prerandomization Randomization . The Prerandomization Phase consist 2 period : Screening ( 4 week ) Baseline ( 4 8 week , depend accuracy diary-documented seizure Screening ) , participant assess eligibility participate study . The Randomization Phase consist 3 period : Titration ( 4 week ) , Maintenance ( 13 week ) , Follow-up ( 4 week ; participant enter Extension Phase ) . At start Randomization Phase , eligible participant randomize perampanel placebo treatment group 1:1 ratio . The extension phase consist 142 week .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Inclusion : 1 . Clinical diagnosis PGTC seizure ( without subtypes primary generalized seizure ) experience great equal 3 PGTC seizure 8week period prior randomization 2 . Have routine electroencephalogram ( EEG ) prior Baseline Period electroencephalographic feature consistent primary generalize epilepsy ; concomitant anomaly explain adequate past medical history 3 . On fix dose one maximum three concomitant antiepileptic drug ( AEDs ) minimum 30 day prior Baseline ; one inducer AED ( i.e. , carbamazepine , oxcarbazepine , phenytoin ) maximum two AEDs allow 4 . A vagal nerve stimulator ( VNS ) allow , must implant great equal 5 month prior Baseline ( stimulator parameter change 30 day prior Baseline duration study ) . 5 . Have compute tomography ( CT ) magnetic resonance imaging ( MRI ) within last 10 year ( adult ) 5 year ( adolescent ) rule progressive cause epilepsy 6 . A ketogenic diet allow long participant diet 5 week prior randomization Exclusion : 1 . A history status epilepticus require hospitalization within 12 month prior Baseline 2 . Seizure cluster individual seizure count 3 . A history psychogenic seizures 4 . Concomitant diagnosis Partial Onset Seizures ( POS ) 5 . Progressive neurological disease 6 . Clinical diagnosis LennoxGastaut syndrome 7 . If felbamate use concomitant AED , participant must felbamate least 2 year , stable dose 60 day prior Baseline . They must history white blood cell ( WBC ) count less equal 2500/microL ( 2.50 1E+09/L ) , platelets less 100,000/microL , liver function test ( LFTs ) great 3 time upper limit normal ( ULN ) , indication hepatic bone marrow dysfunction receive felbamate . 8 . Concomitant use vigabatrin : Participants take vigabatrin past must discontinue approximately 5 month prior Baseline , must documentation show evidence vigabatrinassociated clinically significant abnormality automate visual perimetry test 9 . Concomitant use barbiturate ( except seizure control indication ) within 30 day prior Baseline 10 . Use intermittent rescue benzodiazepine ( i.e. , one two dose 24hour period consider onetime rescue ) two time within 30 day prior Baseline</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Central Nervous System</keyword>
</DOC>